Concordia Healthcare Corporation (CHEHF: OTCQX

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Concordia Healthcare Corporation (CHEHF: OTCQX International) | Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition

Concordia Healthcare Announces Successful Completion of Donnatal® Acquisition

Canada NewsWire

TORONTO , May 15, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), announced today that it has completed the previously announced acquisition of Donnatal ® , an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

"I am extremely pleased with this landmark achievement as it demonstrates Concordia's ability to successfully close a transaction of this magnitude, thereby opening the Company to a new level of acquisition opportunities in the future," said Mark Thompson , CEO of Concordia . "Further, the substantial anticipated revenue to be generated by Donnatal ® is expected to have a significant and positive impact on Concordia's net earnings and EBITDA."

Donnatal ® is available in two formulations: immediate release Donnatal ® Tablets, and immediate release Donnatal ® Elixir, a fast acting liquid.  For decades, Donnatal ® has delivered gentle relief from the symptoms of IBS.  In addition to the drug, Concordia is acquiring the sales and marketing infrastructure related to the product.

The International Foundation for Functional Gastrointestinal Disorders reports that irritable bowel syndrome affects between 25 and 45 million people in the United States (10 to 15 percent of the population) with a greater incidence in women.  According to the National Institutes of Health, as many as 30 percent of Americans suffer from IBS at some time in their lives. It is not associated with hospitalization and surgery, but it can severely compromise a person's quality of life.

IBS is second only to the common cold as a cause of absenteeism from work. IBS is one of the top 10 reasons for physician visits and the second most frequently encountered diagnosis in clinical practice, accounting for more physician visits than any symptoms other than those for respiratory tract infections.

"Donnatal ® is a medication that I have been prescribing for decades.  It remains an effective treatment and provides value for the management of symptoms of irritable bowel syndrome," said Dr. David A. Peura , MD, Emeritus Professor of Medicine at University of Virginia , former President and Chairman of the Board of Governors of the American Gastroenterological Association ("AGA") and recipient of the 2011 Julius Friedenwald Medal , the highest honor awarded by the AGA.

During 2013, Donnatal ® generated revenues of US$49.1 million and EBITDA 1 of US$40.2 million .

The Company acquired Donnatal ® for US$200 million in cash and an aggregate of 4,605,833 common shares of Concordia, representing approximately 16.17% of the Company's outstanding common shares on a non-diluted basis (approximately 14.96% on a fully-diluted basis) after giving effect to the acquisition.  At the closing of the acquisition, Paul Manning , founder of PBM Capital Group and Revive Pharmaceuticals, was appointed to the board of directors of the Company.

Management paid for the cash component of the acquisition through a combination of available cash and debt financing.  Accordingly, the Company entered into a secured credit facility having a principal amount of up to US$195 million , consisting of a US$170 million term loan and a US$25 million operating line (the "Credit Facility") with GE Capital, Healthcare Financial Services and a syndicate of lenders.  The Credit Facility is secured by the assets of the Company and the assets of its material subsidiaries.

Torreya Partners and GMP Securities acted as financial advisors to Concordia . Lazard Middle Market acted as financial advisor to Revive Pharmaceuticals.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. The Company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay ® (clonidine extended release tablets), Ulesfia ® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT ® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin ® in the United States .

Concordia operates out of facilities in Oakville, Ontario , Lenexa, Kansas (near Kansas City, Missouri ), Bannockburn , (near Chicago ), Illinois and Bridgetown, Barbados .

About Revive Pharmaceuticals

Charlottesville, Virginia -based Revive Pharmaceuticals is a privately held specialty pharmaceutical company that specializes in selling, distributing, marketing and manufacturing Rx products that help improve patients' health and quality of life. 

1 As used herein, "EBITDA" is defined as net income adjusted for net interest expense, income tax expense, depreciation and amortization. Management uses EBITDA to assess operating performance.

Non-IFRS Measures

This press release makes reference to certain non-IFRS measures. These non-IFRS measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS, and are therefore unlikely to be comparable to similar measures presented by other companies.  When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure.  These measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective.  Accordingly, they should not be considered in isolation nor as a substitute for analyses of the Company's financial information reported under IFRS.  Management uses non-IFRS measures such as EBITDA and Adjusted EBITDA to provide investors with a supplemental measure of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures.  Management also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers.  Management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess its ability to meet future debt service, capital expenditure, and working capital requirements.

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Concordia and its business, which may include, but is not limited to, statements with respect to the acquisition, the impact of the acquisition on Concordia's financial performance (including its net earnings and EBITDA), Concordia's growth and other factors.  Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of Concordia's management, and are based on assumptions and subject to risks and uncertainties.  Although Concordia's management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Concordia , including risks regarding the pharmaceutical industry, the failure to obtain regulatory approvals, economic factors, market conditions, the equity markets generally, risks associated with growth and competition, risks associated with the acquisition and many other factors beyond the control of Concordia .  Although Concordia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Concordia undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. 

SOURCE Concordia Healthcare Corp.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 0

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 240

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 211

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 46

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 140

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 40

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 109

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading

Top 5 Most Recently Viewed Articles

Qubic's Game-Changing Milestone in Proof of Work Innovation

Updated Category News Views 335

Revolutionizing Mining: Qubic's Major Milestone Qubic, a decentralized compute and AI Layer 1 protocol, has reached a significant milestone with the successful implementation of its Useful Proof of Work (uPoW) concept. By harnessing the potential of merge mining with Monero and Tari, Qubic is setting a new standard in the mining industry and redefining the dynamics of...

Continue Reading
Global Ship Lease's Strong Q3 2024 Performance and Future Outlook

Updated Category News Views 187

Global Ship Lease Reports Impressive Third Quarter of 2024 Global Ship Lease, Inc. (NYSE: GSL), a key player in the containership ownership market, has recently revealed its unaudited financial results for the third quarter of 2024, reflecting strong operational performance and strategic positioning in an evolving maritime landscape. Quarterly Highlights: A Solid...

Continue Reading
Silverfort's New Security Features Enhance Identity Protection

Updated Category News Views 210

Enhancing Identity Security with Silverfort's New Capabilities Silverfort has recently announced exciting advancements in its identity security solutions, solidifying its leadership within the emerging identity verification and identity protection (IVIP) market. The introduction of Access Intelligence and Identity Graph & Inventory empowers organizations to proactively...

Continue Reading
Gabelli Multimedia Trust Maintains Steady Monthly Dividends

Updated Category News Views 306

Gabelli Multimedia Trust's Commitment to Shareholders The Gabelli Multimedia Trust Inc. (NYSE: GGT), located in RYE, N.Y., has reaffirmed its commitment to provide regular monthly cash distributions for its shareholders. This initiative emphasizes the Fund's dedication to maintaining a stable income stream, reflecting its solid financial strategies aimed at long-term...

Continue Reading
Shabodi Launches NetAware 2.1 to Transform Network Applications

Updated Category News Views 170

Shabodi Unveils NetAware 2.1: A Game-Changer for Programmable Networks Shabodi has proudly announced the launch of its innovative platform, NetAware 2.1, marking another significant stride in the realm of programmable networks. This advanced version embodies Shabodi's commitment to enhancing network-aware applications, offering a suite of capabilities that empower...

Continue Reading